Related Experiment Video
Updated: Jul 6, 2026

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
Published on: February 17, 2019
Stem and progenitor cell-mediated tumor selective gene therapy
K S Aboody1, J Najbauer, M K Danks
1Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA. kaboody@coh.org
Abstract:
The poor prognosis for patients with aggressive or metastatic tumors and the toxic side effects of currently available treatments necessitate the development of more effective tumor-selective therapies. Stem/progenitor cells display inherent tumor-tropic properties that can be exploited for targeted delivery of anticancer genes to invasive and metastatic tumors. Therapeutic genes that have been inserted into stem cells and delivered to tumors with high selectivity include prodrug-activating enzymes (cytosine deaminase, carboxylesterase, thymidine kinase), interleukins (IL-2, IL-4, IL-12, IL-23), interferon-beta, apoptosis-promoting genes (tumor necrosis factor-related apoptosis-inducing ligand) and metalloproteinases (PEX). We and others have demonstrated that neural and mesenchymal stem cells can deliver therapeutic genes to elicit a significant antitumor response in animal models of intracranial glioma, medulloblastoma, melanoma brain metastasis, disseminated neuroblastoma and breast cancer lung metastasis. Most studies reported reduction in tumor volume (up to 90%) and increased survival of tumor-bearing animals. Complete cures have also been achieved (90% disease-free survival for >1 year of mice bearing disseminated neuroblastoma tumors). As we learn more about the biology of stem cells and the molecular mechanisms that mediate their tumor-tropism and we identify efficacious gene products for specific tumor types, the clinical utility of cell-based delivery strategies becomes increasingly evident.
Insights
Stem cells target tumors, delivering therapeutic genes to fight aggressive cancers. This cell-based therapy shows significant tumor reduction and improved survival in animal models, offering a promising new treatment approach.
Area of Science:
- Oncology
- Stem Cell Biology
- Gene Therapy
Background:
- Aggressive and metastatic tumors have poor prognoses.
- Current cancer treatments cause toxic side effects.
- Need for more effective, tumor-selective therapies.
Purpose of the Study:
- To investigate the potential of stem/progenitor cells for targeted anticancer gene delivery.
- To evaluate the efficacy of stem cell-mediated gene therapy in preclinical cancer models.
Main Methods:
- Utilizing stem cells (neural and mesenchymal) engineered to carry therapeutic genes.
- Delivering these engineered stem cells to various metastatic tumor models in animals.
- Assessing tumor volume, animal survival, and disease-free survival rates.
Main Results:
- Demonstrated significant antitumor responses in animal models.
- Reported substantial tumor volume reduction (up to 90%).
- Achieved increased survival and complete cures in some models (e.g., 90% disease-free survival in neuroblastoma).
Conclusions:
- Stem cells possess inherent tumor-tropic properties for targeted gene delivery.
- Cell-based gene therapy is a promising strategy for treating invasive and metastatic cancers.
- Further research into stem cell biology and gene product efficacy will enhance clinical utility.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Gene Therapy
Gene Therapy
Tumor Immunotherapy
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

